NCT02220634View on ClinicalTrials.gov

Regadenoson for Acute Vasoreactivity Testing in Pulmonary Hypertension

NATerminatedINTERVENTIONAL

Enrollment

10

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

May 25, 2017

Study Completion Date

May 25, 2017

Conditions

Pulmonary Hypertension

Interventions

DRUG

Regadenoson

Injection for intravenous administration

Trial Locations (1)

80206

National Jewish Health, Denver

Sponsors

Collaborators (1)

Astellas Pharma Inc

All Listed Sponsors

collaborator

Astellas Pharma Inc

INDUSTRY

lead

National Jewish Health

OTHER